Why “Argus 2” Needs Careful Interpretation
Searches for “Argus 2” are often looking for the Argus II Retinal Prosthesis System developed by Second Sight Medical Products, the neurotechnology business now continued by Cortigent. The device became one of the best-known examples of a retinal visual prosthesis because it moved beyond laboratory prototypes into human implantation, regulatory authorization, rehabilitation, and long-term follow-up.
For students, biomedical researchers, engineers, ophthalmology writers, and first-time authors, however, Argus II is easy to oversimplify. Calling it a device that “made blind people see again” can distort both the clinical evidence and the lived experience of artificial vision. The system generated limited patterns of visual perception rather than normal sight. It also had a narrowly defined intended population, required surgery and rehabilitation, produced variable functional outcomes, and was eventually discontinued commercially.
This guide explains the system in research-ready language. It separates mechanism, regulatory status, clinical evidence, safety, limitations, and present-day relevance so that an academic paper, dissertation, literature review, or technology overview can describe Argus II without exaggerated claims.
Quick Answer: What Is Argus 2?
Argus 2 is a common search spelling for Argus II, an epiretinal prosthesis designed to provide limited artificial visual perception to people with severe to profound retinitis pigmentosa. A camera mounted on glasses captured a scene, a video-processing unit translated the image into stimulation commands, and an implanted electrode array stimulated the retina electrically.
The U.S. FDA authorized Argus II in 2013 under a Humanitarian Device Exemption for a narrowly defined patient group. Published studies reported improvements in selected visual tasks for some participants when the system was on, but this was not restoration of ordinary vision. Cortigent now describes Argus II as discontinued and no longer available, while positioning it as a technological foundation for later neurostimulation work.
For academic writing, the most important caution is to distinguish artificial visual perception from normal visual restoration, and to distinguish an FDA Humanitarian Device Exemption from conventional proof of effectiveness.
Key Takeaways
- Argus II was an implanted retinal neuroprosthesis intended for a specific group of adults with severe to profound retinitis pigmentosa.
- The system converted camera images into electrical stimulation patterns delivered through an epiretinal electrode array.
- Users generally perceived light patterns, contrast, location, or motion cues rather than normal-resolution biological vision.
- The FDA authorized Argus II in 2013 under a Humanitarian Device Exemption, a regulatory pathway with specific evidentiary standards.
- Peer-reviewed trials reported functional benefits on some tasks, alongside procedure- and device-related adverse events.
- Cortigent states that Argus II sales were discontinued in 2019 and that the product is no longer available.
- Research papers should describe the device with precise language, primary-source citations, and clear separation between historical evidence and current availability.
What This Page Covers
- What Argus II was
- How the system worked
- Who it was designed for
- Clinical evidence and outcomes
- Safety and limitations
- Why it was discontinued
- How to write about it accurately
Methodology and Academic Sources
This article is based on the U.S. FDA Humanitarian Device Exemption record for Argus II, peer-reviewed PubMed-indexed clinical studies, and current information from Cortigent, the company that continues the former Second Sight neurostimulation business. These sources serve different purposes: regulatory records define authorization and indications; clinical publications report observed outcomes and adverse events; the company’s current website clarifies commercial status and technology lineage.
Biomedical authors should avoid treating any single source as sufficient for every claim. A manufacturer page is useful for current product status but should not replace a peer-reviewed paper when reporting clinical outcomes. A clinical trial paper can characterize observed performance but does not by itself establish present commercial availability. An FDA record can define the authorized indication but must be interpreted according to the Humanitarian Device Exemption framework.
What Argus II Means in a Biomedical Research Context
Argus II is best understood as a retinal neuroprosthesis: an electronic system intended to bypass part of the damaged photoreceptor pathway and deliver patterned electrical stimulation to surviving retinal neurons. It belongs to the broader field of visual prosthetics, which includes retinal implants, optic-nerve approaches, and cortical visual prostheses.
Retinal Prosthesis
An implanted device that electrically stimulates retinal tissue to create visual percepts when normal photoreceptor function has been severely lost.
Epiretinal Array
An electrode array positioned on the inner retinal surface, close to retinal ganglion cells. Argus II used this approach.
Retinitis Pigmentosa
A group of inherited retinal disorders involving progressive photoreceptor degeneration. Argus II’s U.S. authorization was limited to severe-to-profound disease meeting specific criteria.
Artificial Vision
Perceptual information generated through electrical stimulation. It can support detection or orientation tasks but should not be equated with restored natural sight.
The distinction between retinal structure and visual function matters. Argus II depended on surviving inner retinal pathways and an intact route from the eye toward the brain. That is why it was not a universal treatment for blindness. A device that stimulates the retina cannot simply be assumed to help people whose blindness originates primarily in the optic nerve or visual cortex.
How Did the Argus II Retinal Prosthesis Work?
Argus II created a camera-to-retina signal pathway rather than repairing photoreceptors. Its main components worked together in a sequence that converted visual scenes into electrical stimulation.
| Component | Function | What researchers should say carefully |
|---|---|---|
| Camera on glasses | Captured the visual scene in front of the user. | The camera was not itself the implant; it provided external visual input. |
| Video processing unit | Converted image information into stimulation commands. | Image processing reduced and transformed the scene; it did not reproduce natural retinal coding in full detail. |
| Wireless transmission | Sent processed information from the external system to implanted electronics. | The system combined implanted and wearable hardware. |
| Epiretinal electrode array | Delivered electrical stimulation to the retinal surface. | Stimulation produced percepts such as flashes or patterned light rather than normal pixel-for-pixel vision. |
| Visual rehabilitation | Helped users learn how to interpret the new perceptual signals. | Functional benefit depended on training and adaptation, not surgery alone. |
This architecture explains why “60 electrodes” should not be translated simplistically into “60-pixel vision.” Electrical stimulation interacts with retinal tissue, electrode placement, current spread, neural survival, perceptual learning, and individual biology. A technical paper should therefore avoid direct equivalence between electrode count and conventional display resolution unless the claim is explicitly defined and sourced.
Argus II Regulatory and Clinical Timeline
Argus II moved through a sequence of development, implantation studies, regulatory authorization, commercial use, and discontinuation. For research writing, chronology helps prevent outdated statements from being presented as current facts.
- Clinical investigation: Multicenter research evaluated implantation, safety, objective visual-function tasks, and real-world functional performance in people with profound vision loss from retinitis pigmentosa.
- European commercial authorization: The system received European authorization earlier in the decade, establishing Argus II as one of the first commercial retinal prosthesis systems.
- U.S. Humanitarian Device Exemption in 2013: The FDA authorized Argus II for a defined adult population with severe to profound retinitis pigmentosa under the HDE pathway.
- Post-approval follow-up: Investigators continued assessing adverse events, device performance, functional vision, and long-term durability.
- Sales discontinued in 2019: Cortigent states that sales were stopped as development attention shifted toward the Orion cortical visual prosthesis program.
- Current research legacy: Argus II remains important in the literature because it provides real-world evidence about implantable visual prostheses, rehabilitation, safety, regulatory pathways, user adaptation, and the challenges of maintaining long-term neurotechnology platforms.
What Did Argus II Studies Actually Find?
The evidence is most accurately summarized as task-specific improvement for some users, combined with meaningful limitations and clinically important adverse events. It is not accurate to reduce the literature to either “the device restored sight” or “the device did not work.”
A five-year multicenter study followed 30 implanted participants and evaluated safety and visual performance using within-participant comparisons that included system-on and system-off conditions. Published findings supported sustained performance differences on selected visual-function measures for a number of participants. Other studies examined functional activities such as localization, movement direction, object interaction, and real-world tasks.
One object-localization and prehension study of five blind participants, for example, reported that participants could initiate and successfully complete visually guided reaching tasks with the prosthesis on, whereas the same visually driven task could not be initiated with the prosthesis off under the study conditions. This kind of finding is important, but it should not be generalized beyond the task, sample, and study design.
| Evidence type | What it can support | What it cannot automatically prove |
|---|---|---|
| Computer-based visual tasks | Differences in localization, motion, or grating performance under test conditions. | Normal vision or independence in everyday life. |
| Functional vision tasks | Whether artificial visual cues can assist selected real-world activities. | Equal benefit across all users, settings, or activities. |
| Long-term follow-up | Durability, adverse-event patterns, and continued device use among followed participants. | Absence of long-term risk for every implanted person. |
| Patient reports | How individuals experience and use artificial visual percepts. | A standardized measure of visual acuity unless tested with a validated protocol. |
| Regulatory authorization | That the device met requirements of the applicable regulatory pathway for the defined indication. | Conventional proof that effectiveness was demonstrated for all potential users. |
A Better Way to Describe Clinical Benefit
Use language such as “provided limited artificial visual perception,” “improved performance on selected tasks in some participants,” or “supported detection, localization, or orientation under defined conditions.” These phrases are more faithful to the literature than broad statements such as “restored vision” unless the term is carefully qualified.
Why Sample Size and Study Design Matter
Visual-prosthesis trials often involve small populations because the eligible patient group is narrow and implantation is complex. Small cohorts do not invalidate the research, but they affect precision, generalizability, subgroup analysis, and the strength of conclusions. Authors should report participant numbers, follow-up periods, comparison conditions, and outcome measures rather than presenting a headline result without context.
Safety, Surgery, Device Maintenance, and Rehabilitation
Argus II required far more than implantation. The system combined ophthalmic surgery, implanted electronics, external equipment, device fitting, software or processing configuration, and structured visual rehabilitation. A complete academic description should recognize the entire care pathway.
The FDA indication required patients to be willing and able to receive recommended post-implant clinical follow-up, device fitting, and visual rehabilitation. That requirement is conceptually important: neuroprosthetic benefit emerges from the interaction of hardware, biology, calibration, and learning.
Safety reporting also needs precision. A post-approval study involving 47 patients followed for at least one year reported both nonserious and serious adverse events, including conjunctival erosion among the serious events. The correct academic practice is to identify the study, population, follow-up period, and event definitions rather than convert those observations into a blanket statement about safety.
Limitations, Ethics, and Common Misstatements About Argus 2
The most common writing problem is exaggeration. Argus II was historically significant precisely because it delivered useful artificial visual information despite severe engineering and biological constraints. Overselling its performance actually weakens the scientific story.
Misstatement 1: “Argus II restored normal sight.”
A better description is that the system produced artificial visual percepts that could improve performance on selected tasks for some users. Natural human vision includes high acuity, color, depth, motion processing, wide-field integration, eye movements, adaptation, and complex cortical interpretation. Argus II did not reproduce that full system.
Misstatement 2: “FDA approved means effectiveness was proven like a standard medical device.”
Argus II was authorized under a Humanitarian Device Exemption. The FDA’s original authorization record specifies the intended population and the HDE framework. Researchers should use the exact regulatory terminology and avoid flattening meaningful distinctions between pathways.
Misstatement 3: “Argus II is a current treatment option.”
That is outdated. Cortigent says the product has been discontinued and is no longer available. Historical articles may correctly describe former commercialization, but present-tense recommendations must reflect current status.
Misstatement 4: “The implant alone created the outcome.”
The external camera, processing hardware, wireless link, implanted array, fitting, rehabilitation, user learning, and remaining neural pathways all contributed to system function. An implant-only description is incomplete.
Misstatement 5: “Argus II and Orion are the same technology.”
They share a neurostimulation lineage, but their anatomical targets differ. Argus II stimulated the retina; Orion is designed to stimulate the visual cortex and remains investigational. That distinction affects intended populations, surgical approach, neural pathway assumptions, and clinical development.
Practical Research Writing Examples
Good biomedical writing does not merely add references; it calibrates the claim to the evidence. The examples below show how to turn common overstatements into publication-ready academic language.
“Argus II allowed blind patients to see normally.”
Better: “Argus II provided limited artificial visual percepts and improved performance on selected visual-function tasks in some participants with profound vision loss from retinitis pigmentosa.”
“Argus II is an available retinal implant for RP.”
Better: “Argus II was commercially deployed for a defined retinitis pigmentosa population but has since been discontinued; it remains an important historical platform in visual-prosthesis research.”
“The FDA proved Argus II was effective.”
Better: “The FDA authorized Argus II in 2013 under a Humanitarian Device Exemption for a specified patient population; clinical studies separately reported safety and task-specific performance outcomes.”
In a literature review, this calibrated style helps readers distinguish evidence strength. In a discussion chapter, it also makes comparison with other prosthetic approaches more meaningful because the author is not comparing exaggerated claims.
Academic Accuracy Checklist for Writing About Argus II
Before Drafting
- Decide whether your topic is retinal prostheses, retinitis pigmentosa, neurostimulation, rehabilitation, regulatory science, or the history of bionic vision.
- Use “Argus II Retinal Prosthesis System” on first mention; explain that “Argus 2” is a common search variation.
- Collect primary regulatory and peer-reviewed clinical sources before relying on secondary summaries.
While Writing
- Separate device mechanism from clinical outcome.
- State that visual percepts were limited and not equivalent to normal vision.
- Specify the target population rather than describing Argus II as a general blindness treatment.
- Report participant numbers, follow-up periods, outcome measures, and system-on/system-off comparisons where relevant.
- Distinguish HDE authorization from conventional effectiveness claims.
- Use present tense only for facts that remain current, such as the product’s discontinued status.
Before Submission
- Check that every numerical result matches the cited study.
- Verify that company and regulatory status statements are current.
- Confirm terminology consistency: retinal prosthesis, epiretinal array, artificial vision, visual perception, and retinitis pigmentosa.
- Review tables and figures for unsupported simplifications such as equating electrode count with normal pixels.
- Follow the target journal’s reference style, medical-device terminology, and reporting requirements.
How Contentxprtz Can Help With a Retinal Prosthesis Research Paper
For a topic such as Argus II, professional academic editing is most useful when the research is already yours but the manuscript needs stronger clarity, structure, terminology control, and source-to-claim alignment. The editor’s role should be to improve communication without replacing the researcher’s scientific judgment.
Contentxprtz can help researchers refine literature reviews, discussion sections, methods descriptions, tables, figure captions, references, and journal-facing language. For ESL authors, editing can also reduce ambiguity in technical sentences while preserving the intended scientific meaning.
Preparing a paper on retinal prostheses or biomedical devices?
Improve clarity, academic tone, terminology consistency, and publication readiness while keeping authorship and scientific interpretation with you.
Useful Authoritative Sources to Check
For final verification, consult the FDA Humanitarian Device Exemption record, the five-year clinical study indexed in PubMed, the one-year post-approval safety and performance study, and Cortigent’s current Argus II product-status page. When a journal article makes a numerical claim, cite the underlying publication rather than a marketing summary.
Summary: Argus 2 as a Landmark Retinal Prosthesis
Argus 2, more accurately written as Argus II, was a pioneering epiretinal prosthesis for a narrowly defined group of people with severe to profound retinitis pigmentosa. It used a glasses-mounted camera, external video processing, wireless transmission, and a retinal electrode array to produce limited artificial visual percepts.
The research record shows why Argus II is scientifically important: it demonstrated that implanted retinal stimulation could provide useful visual information in human participants over extended periods, while also revealing major limitations in resolution, variability, surgical risk, rehabilitation needs, and long-term technology support. The device was authorized in the United States under an HDE in 2013 and was later discontinued commercially.
For researchers, the strongest article or thesis section will neither celebrate Argus II uncritically nor dismiss it because it did not reproduce natural vision. Instead, it will explain what the device actually did, what its studies measured, where the evidence was strongest, what risks and limitations were reported, and how the platform informed later visual-neuroprosthesis development.
Questions About Argus 2 and the Argus II Retinal Prosthesis
These answers are written for students, researchers, and authors who need concise, academically careful explanations.
What is Argus 2?
Argus 2 is commonly used as a search variation for the Argus II Retinal Prosthesis System, an epiretinal neuroprosthesis developed by Second Sight Medical Products for people with severe to profound retinitis pigmentosa. It used a camera, a video-processing unit, wireless transmission, and a retinal electrode array to create patterns of electrical stimulation that users could learn to interpret as visual percepts. It did not restore normal eyesight.
Is Argus II still available?
No. Cortigent, the company that continues the former Second Sight neurostimulation business, states that Argus II has been discontinued and is no longer available. Cortigent says sales were discontinued in 2019 as the company refocused the underlying technology on the Orion cortical visual prosthesis program.
Was Argus II approved by the FDA?
The U.S. Food and Drug Administration authorized Argus II in 2013 under a Humanitarian Device Exemption for a specific population of adults with severe to profound retinitis pigmentosa who met defined criteria. An HDE is not the same as a conventional effectiveness approval, and the FDA labeling framework explicitly distinguishes probable benefit from demonstrated effectiveness.
How did Argus II work?
A miniature camera mounted on glasses captured images. A body-worn video processing unit converted those images into stimulation patterns, which were transmitted wirelessly to an implanted epiretinal electrode array. The array electrically stimulated remaining retinal cells, and signals traveled through the visual pathway to produce perceptions such as light patterns, contrast, or motion cues.
Did Argus II restore normal vision?
No. Published studies reported improvements in selected visual-function or real-world tasks for some participants when the system was switched on, but the artificial percepts were limited and did not reproduce normal biological vision. Outcomes varied by participant and task.
What did the five-year Argus II study find?
A multicenter five-year study of 30 implanted participants reported long-term safety data and sustained performance on several visual-function measures. The study supported the possibility of useful artificial visual information for some users, but it did not mean that normal visual acuity or ordinary sight was restored.
What risks were reported with Argus II?
Clinical studies reported device- and procedure-related adverse events. In a one-year post-approval study of 47 patients, serious adverse events included conjunctival erosion among other events. Researchers should report study-specific safety findings rather than describe the device as simply safe or unsafe.
What is the difference between Argus II and Orion?
Argus II stimulated the retina and was intended for a narrow group of people with advanced retinitis pigmentosa and a functioning downstream visual pathway. Orion is an investigational cortical visual prosthesis designed to stimulate the visual cortex, with the goal of addressing blindness from a wider range of causes. Orion remains investigational and is not a replacement product that readers should assume is commercially available.
How should researchers write about Argus II accurately?
Use the full device name on first mention, distinguish regulatory authorization from proof of effectiveness, separate technical mechanism from clinical outcomes, state that the product has been discontinued, and cite primary sources such as FDA records and peer-reviewed clinical studies. Avoid describing the system as restoring sight in a normal or complete sense.
Can Contentxprtz help edit a paper about retinal prostheses?
Yes, when the need is editorial rather than clinical. Contentxprtz can help researchers improve structure, language, terminology consistency, references, tables, figure captions, and journal-readiness while preserving author responsibility for scientific interpretation and factual claims.
Write About Argus II With Precision, Not Hype
The main research challenge with Argus II is not finding a dramatic story; it is describing a historically important neuroprosthesis without allowing dramatic language to outrun the evidence. The device created limited artificial visual perception for a specific population, required surgery and rehabilitation, produced variable task-level benefits, and involved meaningful risks and practical constraints.
For a short assignment, a careful explanation of mechanism, indication, evidence, and discontinued status may be enough. For a dissertation, systematic review, or journal manuscript, researchers should go further by evaluating trial design, outcome measures, adverse-event reporting, patient-reported function, regulatory context, technology lifecycle, and comparisons with retinal or cortical alternatives.
Expert academic editing can be helpful when the scientific argument is sound but the manuscript needs clearer structure, stronger transitions, consistent terminology, reference checking, or language polishing. The author remains responsible for data interpretation, clinical claims, ethics, and the final submitted work.
“At Contentxprtz, we don’t just edit; we help ideas reach their fullest potential.”